Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
10/2003
10/01/2003CN1444929A Fibrauretine dispersant tablet and its preparing method
10/01/2003CN1122516C Medicine for treating oral and throat disease
10/01/2003CN1122513C Use of compound in medicine for preparation of inhibiting pathological conditions
09/2003
09/30/2003US6627754 Pyrrolo[2,3-d]pyrimidine compounds
09/30/2003US6627656 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
09/30/2003US6627649 (2S)-1-((2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4 -dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2 -carbonyl)pyrrolidine-2-carboxamide, a selective V1a arginine vasopressin receptor antagonist, in combination with the
09/30/2003US6627644 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists
09/30/2003US6627637 I kappa B kinase inhibitors for treating various disorders including arthritis
09/30/2003US6627630 Preventing or treating allergic skin diseases such as contact dermatitis, pruritus, dried dermatitis, acute urticaria prurigo and antiallergins
09/30/2003US6627629 Useful for the treatment or prevention of asthma and other allergic diseases.
09/30/2003US6627628 Cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) are able to modulate the body's own production of cyclic guanosine monophosphate (cGMP) and are suitable for
09/30/2003US6627626 Antiinflammation agents and antiarthritic agents colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
09/30/2003US6627621 Neutrophil function inhibitors
09/30/2003US6627615 Methods and compositions for in vivo gene therapy
09/30/2003US6627602 Preventing desensitization of receptors
09/30/2003US6627195 Binding agents to CD23
09/30/2003CA2108788C Liposomal prostaglandin formulations
09/25/2003WO2003078632A1 Novel receptor polypeptides and polynucleotides encoding the same
09/25/2003WO2003078609A1 Methods of inducing differentiation of stem cells into a specific cell lineage
09/25/2003WO2003078608A1 Methods of inducing differentiation of stem cells into a specific cell lineage
09/25/2003WO2003078579A2 Compositions and methods for treating emphysema
09/25/2003WO2003078435A1 Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
09/25/2003WO2003078429A1 Micronized crystalline tiotropium bromide
09/25/2003WO2003078428A1 Difurylglycolic acid tropenol esters used as anticholinesterase drugs
09/25/2003WO2003078422A1 Novel pyridone derivative
09/25/2003WO2003078421A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003078419A1 N-substituted benzothiophenesulfonamide derivative
09/25/2003WO2003078413A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity
09/25/2003WO2003078409A1 Carboxyoic acid compounds and drugs containing the compounds as the active ingredient
09/25/2003WO2003078404A1 Pyrimidine derivatives
09/25/2003WO2003078397A1 Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
09/25/2003WO2003078395A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003078376A1 Nk1 antagonists
09/25/2003WO2003078361A1 Controlling chemical reactions by spectral chemistry and spectral conditioning
09/25/2003WO2003077949A2 Methods of treating diabetes using pde 11a inhibitors
09/25/2003WO2003077947A1 Methods of modulating cd200 receptors
09/25/2003WO2003077932A1 Remedies for lung cancer
09/25/2003WO2003077915A1 Use of rapamycin for inhibiting of cell death
09/25/2003WO2003077907A1 Azetidine derivatives as ccr-3 receptor antagonists
09/25/2003WO2003077892A2 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases
09/25/2003WO2003077865A2 Methods and compositions for directing cells to target organs
09/25/2003WO2003077864A2 Methods and compositions for directing cells to target organs
09/25/2003WO2003077847A2 Substituted amides
09/25/2003WO2003077832A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003WO2003077657A1 Choline-silicic acid complex with osmolytes and divalent trace elements
09/25/2003WO2003070738A3 Topiramate salts and compositions comprising and methods of making and using the same
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003039451A3 Thiazole pyridazinones as adenosine antagonists
09/25/2003WO2003029199A9 Benzene derivatives, process for preparing the same and use thereof
09/25/2003WO2003020219A3 Aerosolized decongestants for the treatment of sinusitis
09/25/2003WO2003013537A3 Irinotecan for treatment of cancer
09/25/2003WO2003013535A3 Use of irinotecan for improved treatment of cancer based on mdr1
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2002094287A3 Identifying parasitic fungi of the organism, and treatment thereof
09/25/2003WO2002074733A3 Tryptase-inhibitors
09/25/2003WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89)
09/25/2003WO2002036573B1 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
09/25/2003US20030181706 Inflammation-associated polynucleotides
09/25/2003US20030181587 Thermoplastic resin composition
09/25/2003US20030181519 Substituted phenyl naphthalenes as estrogenic agents
09/25/2003US20030181518 Compositions and methods for treating cystic fibrosis
09/25/2003US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
09/25/2003US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181489 For therapy and prophylaxis of cough in warm-blooded animals
09/25/2003US20030181469 Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
09/25/2003US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents
09/25/2003US20030181389 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
09/25/2003US20030181356 Treating emphysema by reducing the amount of force the fibers in the lung (e.g., the collagen and elastin fibers in the walls of the alveoli) must bear. The invention features a pharmaceutically acceptable composition comprising lipid for
09/25/2003US20030180877 Gene therapy; drug screening
09/25/2003US20030180349 Administering before or after onset of disease
09/25/2003US20030180337 Use of an (r)-enantiomer of lipoic acid in cosmetics and dermatologicals
09/25/2003US20030180317 Diagnosis ear infections in children
09/25/2003US20030180301 Prevention organ rejection; induction immunology response; reduce fibrosis
09/25/2003US20030180300 Collagen biosynthesis; controlling cell differentiation, cell proliferation
09/25/2003US20030180288 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
09/25/2003US20030180287 Polypeptide formulation
09/25/2003US20030180275 Human serpin polypeptides
09/25/2003US20030180260 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor
09/25/2003US20030180249 Storage stability; mixture containing ion exchange resin
09/25/2003US20030180228 Aerosol container for formulations of salmeterol xinafoate
09/25/2003US20030180227 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
09/25/2003CA2518794A1 Compositions and methods for treating emphysema
09/25/2003CA2479676A1 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003CA2479352A1 Carboxylic acid compound and a pharmaceutical agent comprising the compound as an active ingredient
09/25/2003CA2479266A1 Azetidine derivatives as ccr-3 receptor antagonists
09/25/2003CA2479152A1 Methods of inducing differentiation of stem cells into a specific cell lineage
09/25/2003CA2479141A1 Pyridone derivatives
09/25/2003CA2479069A1 Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
09/25/2003CA2478805A1 Controlling chemical reactions by spectral chemistry and spectral conditioning
09/25/2003CA2478803A1 Methods of modulating cd200 receptors
09/25/2003CA2478795A1 Use of rapamycin for inhibiting cell death
09/25/2003CA2478715A1 Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators
09/25/2003CA2478211A1 Nk1 antagonists
09/25/2003CA2477832A1 Methods of treating diabetes using pde 11a inhibitors
09/25/2003CA2476746A1 Difurylglycolic acid tropenol esters used as anticholinesterase drugs
09/24/2003EP1346982A1 Vla-4 inhibitors
09/24/2003EP1346732A2 Dosage forms for hygroscopic active ingredients
09/24/2003EP1346228A2 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
1 ... 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 ... 878